Bard Financial Services Inc. Has $2.47 Million Position in Kenvue Inc. (NYSE:KVUE)

Bard Financial Services Inc. grew its holdings in Kenvue Inc. (NYSE:KVUE) by 5.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 106,790 shares of the company’s stock after purchasing an additional 5,750 shares during the quarter. Bard Financial Services Inc.’s holdings in Kenvue were worth $2,470,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Soltis Investment Advisors LLC boosted its stake in Kenvue by 3.7% in the third quarter. Soltis Investment Advisors LLC now owns 151,858 shares of the company’s stock worth $3,512,000 after purchasing an additional 5,475 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of Kenvue by 5.6% during the third quarter. TD Private Client Wealth LLC now owns 129,127 shares of the company’s stock worth $2,987,000 after acquiring an additional 6,901 shares during the last quarter. Sunbelt Securities Inc. raised its position in shares of Kenvue by 3.1% during the third quarter. Sunbelt Securities Inc. now owns 29,671 shares of the company’s stock worth $686,000 after acquiring an additional 905 shares during the last quarter. Financial Avengers Inc. raised its position in shares of Kenvue by 15.6% during the third quarter. Financial Avengers Inc. now owns 46,530 shares of the company’s stock worth $1,076,000 after acquiring an additional 6,278 shares during the last quarter. Finally, Coldstream Capital Management Inc. raised its position in shares of Kenvue by 2.6% during the third quarter. Coldstream Capital Management Inc. now owns 26,017 shares of the company’s stock worth $602,000 after acquiring an additional 653 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.7 %

Shares of Kenvue stock opened at $22.90 on Wednesday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The business has a 50-day moving average of $22.96 and a two-hundred day moving average of $21.15. The company has a market capitalization of $43.91 billion, a P/E ratio of 41.35, a price-to-earnings-growth ratio of 2.07 and a beta of 1.37. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the company earned $0.31 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. As a group, equities analysts predict that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.58%. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on KVUE. Bank of America boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. boosted their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday. Finally, Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.